Concepedia

Anna Sylwestrzak

AS

Statistics

Publications

5

Citations

449

H-Index

5

Active since

2015

Affiliations

Institute of Rheumatology(Current)

Samsung (South Korea)

Poznan University of Medical Sciences

University of Leeds

NIHR Leeds Musculoskeletal Biomedical Research Unit

Anna Sylwestrzak is an author at Institute of Rheumatology specializing in rheumatoid arthritis, rheumatology, and medicine.

Publications per year

2015–2017

5

Publications

5

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2015 · 229 citations · Full text

, , +14

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2017 · 110 citations · Full text

, , +14

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Lara D. Veeken · 2017 · 68 citations · Full text

, , +15

FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)

Jiří Vencovský, Anna Sylwestrzak, Piotr Leszczyński et al. · Annals of the Rheumatic Diseases · 2015 · 25 citations

, , +16

THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2016 · 17 citations

, , +15

1–5 of 5